Homology Modeling and Molecular Docking Studies on Type II Diabetes Complications Reduced PPARγ Receptor with Various Ligand Molecules

Peroxisome proliferator-activated receptor gamma (PPARγ), a type II nuclear receptor present in adipose tissue, colon and macrophages. It reduces the hyperglycemia associated metabolic syndromes. Particularly, type II diabetes-related cardiovascular system risk in human beings. The fatty acid storag...

Full description

Bibliographic Details
Main Authors: Prabhu, S., Vijayakumar, S., Manogar, P., Gaanty Pragas, Maniam, Natanamurugaraj, Govindan
Format: Article
Language:English
Published: Elsevier Ltd 2017
Subjects:
Online Access:http://umpir.ump.edu.my/id/eprint/17914/
http://umpir.ump.edu.my/id/eprint/17914/
http://umpir.ump.edu.my/id/eprint/17914/
http://umpir.ump.edu.my/id/eprint/17914/1/Homology%20Modeling%20and%20Molecular%20Docking%20Studies%20on%20Type%20II-1.pdf
id ump-17914
recordtype eprints
spelling ump-179142018-07-13T08:42:23Z http://umpir.ump.edu.my/id/eprint/17914/ Homology Modeling and Molecular Docking Studies on Type II Diabetes Complications Reduced PPARγ Receptor with Various Ligand Molecules Prabhu, S. Vijayakumar, S. Manogar, P. Gaanty Pragas, Maniam Natanamurugaraj, Govindan TP Chemical technology Peroxisome proliferator-activated receptor gamma (PPARγ), a type II nuclear receptor present in adipose tissue, colon and macrophages. It reduces the hyperglycemia associated metabolic syndromes. Particularly, type II diabetes-related cardiovascular system risk in human beings. The fatty acid storage and glucose metabolism are regulated by PPARγ activation in human body. According to recent reports commercially available PPARγ activating drugs have been causing severe side effects. At the same time, natural products have been proved to be a promising area of drug discovery. Recently, many studies have been attempted to screen and identify a potential drug candidate to activate PPARγ. Hence, in this study we have selected some of the bio-active molecules from traditional medicinal plants. Molecular docking studies have been carried out against the target, PPARγ. We Results suggested that Punigluconin has a efficient docking score and it is found to have good binding affinities than other ligands. Hence, we concluded that Punigluconin is a better drug candidate for activation of PPARγ gene expression. Further studies are necessary to confirm their efficacy and possibly it can develop as a potential drug in future. Elsevier Ltd 2017 Article PeerReviewed pdf en http://umpir.ump.edu.my/id/eprint/17914/1/Homology%20Modeling%20and%20Molecular%20Docking%20Studies%20on%20Type%20II-1.pdf Prabhu, S. and Vijayakumar, S. and Manogar, P. and Gaanty Pragas, Maniam and Natanamurugaraj, Govindan (2017) Homology Modeling and Molecular Docking Studies on Type II Diabetes Complications Reduced PPARγ Receptor with Various Ligand Molecules. Biomedicine & Pharmacotherapy, 92. pp. 528-535. ISSN 0753-3322 https://doi.org/10.1016/j.biopha.2017.05.077 doi: 10.1016/j.biopha.2017.05.077
repository_type Digital Repository
institution_category Local University
institution Universiti Malaysia Pahang
building UMP Institutional Repository
collection Online Access
language English
topic TP Chemical technology
spellingShingle TP Chemical technology
Prabhu, S.
Vijayakumar, S.
Manogar, P.
Gaanty Pragas, Maniam
Natanamurugaraj, Govindan
Homology Modeling and Molecular Docking Studies on Type II Diabetes Complications Reduced PPARγ Receptor with Various Ligand Molecules
description Peroxisome proliferator-activated receptor gamma (PPARγ), a type II nuclear receptor present in adipose tissue, colon and macrophages. It reduces the hyperglycemia associated metabolic syndromes. Particularly, type II diabetes-related cardiovascular system risk in human beings. The fatty acid storage and glucose metabolism are regulated by PPARγ activation in human body. According to recent reports commercially available PPARγ activating drugs have been causing severe side effects. At the same time, natural products have been proved to be a promising area of drug discovery. Recently, many studies have been attempted to screen and identify a potential drug candidate to activate PPARγ. Hence, in this study we have selected some of the bio-active molecules from traditional medicinal plants. Molecular docking studies have been carried out against the target, PPARγ. We Results suggested that Punigluconin has a efficient docking score and it is found to have good binding affinities than other ligands. Hence, we concluded that Punigluconin is a better drug candidate for activation of PPARγ gene expression. Further studies are necessary to confirm their efficacy and possibly it can develop as a potential drug in future.
format Article
author Prabhu, S.
Vijayakumar, S.
Manogar, P.
Gaanty Pragas, Maniam
Natanamurugaraj, Govindan
author_facet Prabhu, S.
Vijayakumar, S.
Manogar, P.
Gaanty Pragas, Maniam
Natanamurugaraj, Govindan
author_sort Prabhu, S.
title Homology Modeling and Molecular Docking Studies on Type II Diabetes Complications Reduced PPARγ Receptor with Various Ligand Molecules
title_short Homology Modeling and Molecular Docking Studies on Type II Diabetes Complications Reduced PPARγ Receptor with Various Ligand Molecules
title_full Homology Modeling and Molecular Docking Studies on Type II Diabetes Complications Reduced PPARγ Receptor with Various Ligand Molecules
title_fullStr Homology Modeling and Molecular Docking Studies on Type II Diabetes Complications Reduced PPARγ Receptor with Various Ligand Molecules
title_full_unstemmed Homology Modeling and Molecular Docking Studies on Type II Diabetes Complications Reduced PPARγ Receptor with Various Ligand Molecules
title_sort homology modeling and molecular docking studies on type ii diabetes complications reduced pparγ receptor with various ligand molecules
publisher Elsevier Ltd
publishDate 2017
url http://umpir.ump.edu.my/id/eprint/17914/
http://umpir.ump.edu.my/id/eprint/17914/
http://umpir.ump.edu.my/id/eprint/17914/
http://umpir.ump.edu.my/id/eprint/17914/1/Homology%20Modeling%20and%20Molecular%20Docking%20Studies%20on%20Type%20II-1.pdf
first_indexed 2023-09-18T22:25:03Z
last_indexed 2023-09-18T22:25:03Z
_version_ 1777415910095585280